

Declaration of interests register

Medical Technologies Advisory Committee

Publication Date: 19th January 2022

Topic: MT539 3C Patch System for treating diabetic foot ulcers

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
<i>David Partridge</i>	MTAC member	Indirect financial	<i>He is a co-investigator on a grant application for a study looking at a novel topical antibiotic aimed at treating diabetic foot infections. The work is all early stage pre-clinical at the minute and is not a dressing per se although obviously it aims at treating a small subsection of the same patients.</i>	N/A	<i>February 2021</i>	N/A	Open declaration
<i>Joanne Thorpe</i>	Expert adviser	N/A	N/A	N/A	<i>January 2021</i>	N/A	N/A
<i>Alison Musgrove</i>	Expert adviser	Non-financial professional	<i>Ms Musgrove was an investigator on the trial as a side.</i> <i>Ms Musgrove gave an educational / practical session on the 3CP patch in 2019 on a diabetes foot</i>	N/A 2019	<i>June 2021</i> <i>January 2021</i>	N/A 2019	Open declaration and remain for MTAC Part 1

			<i>module . It comprised of her experience of using it in the trail. She was not paid directly for this but Reaplix offered to pay for accommodation to a conference which had to be cancelled due to COVID in 2020.</i>				
<i>Frances Game</i>	Expert adviser	Non-financial professional	<i>Chief Investigator and first author of the largest RCT of this technology submitted (Game et al 2018) (from 2012 till 2018)</i>	2012	January 2021	2018	Open declaration and remain for MTAC Part 1
<i>Prof Edward Jude</i>	Expert adviser	N/A	<i>N/A</i>	<i>N/A</i>	June 2021	<i>N/A</i>	N/A
<i>Mr Sam Roberts</i>	Patient expert	N/A	<i>N/A</i>	<i>N/A</i>	April 2021	<i>N/A</i>	N/A
<i>York Health Economics Consortium (YHEC)</i>	External Assessment Centre (EAC)	Indirect financial	<i>YHEC are acting as the External assessment centre for the MTEP evaluation of 3CPatch. YHEC have been asked to work on a project for a technology designed to treat hard to heal diabetic foot ulcers (the same indication as 3C Patch.) The company has no other products in this disease area.</i>	<i>N/A</i>	July 2021	<i>N/A</i>	Open declaration and remain for MTAC Part 1